BGI-Shenzhen Extends Tender Offer For Complete Genomics, Inc.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130125:nPnNY48820

SHENZHEN, China, Jan. 25, 2013 /PRNewswire/ -- BGI-Shenzhen ("BGI") announced
today that it, through its wholly-owned subsidiary Beta Acquisition Corporation,
has extended its all cash tender offer (the "Offer") to purchase all outstanding
shares of common stock of Complete Genomics, Inc. (NASDAQ: GNOM) ("Complete") to
12:00 midnight (EST) on Friday, February 1, 2013. The Offer was previously
scheduled to expire at 12:00 midnight (EST) on Friday, January 25, 2013.

Except for the extension of the Offer expiration date, all other terms and
conditions of the Offer remain unchanged. The Depositary for the Offer has
indicated that, as of the close of business on January 25, 2013, approximately
30,949,757 shares, or approximately 87%, of common stock of Complete have been
validly tendered in and not withdrawn from the Offer, including shares of common
stock of Complete subject to guaranteed delivery procedures.

BGI's financial advisor is Citi, and its legal counsel is O'Melveny & Myers LLP.
Complete's financial adviser is Jefferies & Company, and its legal counsel is
Latham & Watkins LLP.

Stockholders with questions about the Offer, or who need assistance with
tendering their shares of common stock of Complete, may call the Information
Agent, Innisfree M&A Incorporated, toll-free at (888) 750-5834.

FORWARD-LOOKING STATEMENTS

Certain statements either contained in or incorporated by reference into this
document are forward-looking statements that involve risks and uncertainty.
Future events regarding the proposed transactions and both BGI's and Complete's
actual results could differ materially from the forward-looking statements.
Factors that might cause such a difference include, but are not limited to,
statements regarding the combined companies' plans following, and the expected
completion of, the proposed acquisition. These forward-looking statements
involve certain risks and uncertainties that could cause actual results to
differ materially from those indicated in such forward-looking statements and
generally include statements that are predictive in nature and depend upon or
refer to future events or conditions. Risks and uncertainties include the
ability of BGI and Complete to complete the transactions contemplated by the
merger agreement, including the parties' abilities to satisfy the conditions to
the consummation of the proposed acquisition; the possibility of any termination
of the merger agreement; the timing of the Offer and the subsequent merger;
uncertainties as to how many of Complete's stockholders will tender their shares
of common stock in the Offer; the possibility that various other conditions to
the consummation of the Offer or the subsequent merger may not be satisfied or
waived, including that a governmental entity may prohibit, delay or refuse to
grant approval for the consummation of the acquisition; other uncertainties
pertaining to the business of Complete or BGI; legislative and regulatory
activity and oversight; the continuing global economic uncertainty and other
risks detailed in Complete's public filings with the Securities and Exchange
Commission (the "SEC") from time to time, including Complete's most recent
Annual Report on Form 10-K for the year ended December 31, 2011, Quarterly
Reports on Form 10-Q and its subsequently filed SEC reports, each as filed with
the SEC, which contains and identifies important factors that could cause actual
results to differ materially from those contained in the forward-looking
statements. The reader is cautioned not to unduly rely on these forward-looking
statements. Each of Complete and BGI expressly disclaims any intent or
obligation to update or revise publicly these forward-looking statements except
as required by law.

ADDITIONAL INFORMATION

This press release is neither an offer to purchase nor a solicitation of an
offer to sell shares of Complete. BGI and Beta Acquisition Corporation filed a
tender offer statement with the SEC on September 25, 2012, and mailed an offer
to purchase, forms of letter of transmittal and related documents to Complete's
stockholders. Complete filed a solicitation/recommendation statement on Schedule
14D-9 with the SEC on September 25, 2012, and mailed the Schedule 14D-9 to
Complete's stockholders. These documents, as they may be amended from time to
time, contain important information about the Offer, and stockholders of
Complete are urged to read them carefully.

Investors may obtain a free copy of these documents and other relevant documents
filed with the SEC through the website maintained by the SEC at www.sec.gov. In
addition, investors and stockholders will be able to obtain free copies of these
materials filed by Complete by contacting Investor Relations by telephone at
(650) 943-2788, by mail at Complete Genomics, Inc., Investor Relations, 2071
Stierlin Court, Mountain View, California 94043, or by going to Complete's
Investor Relations page on its corporate website at www.completegenomics.com.

MEDIA INQUIRIES

For BGI-Shenzhen:
In the U.S.:
Jason Golz
Brunswick Group
Tel: (415) 671-7676
jgolz@brunswickgroup.com

In China:
Elizabeth Liang
Brunswick Group
Tel: +852 3512-5000
eliang@brunswickgroup.com

SOURCE BGI-Shenzhen